Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

HEALTHCARE (NY: XLV )

144.80 -1.59 (-1.09%)
Official Closing Price Updated: 8:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HEALTHCARE

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Health Insurance ETFs in Focus as RFK Jr Takes Over HHS
Robert F. Kennedy Jr. has taken office as HHS secretary, which could impact the healthcare sector, including ETFs with exposure to insurers like UnitedHealth and Elevance Health. 
Via Benzinga
Topics ETFs
Leading And Lagging Sectors For February 17, 2025
Via Benzinga
China, Gold, Momentum Lead, But Surprisingly Savvy Investors Turn Bearish
Momentum stocks are leading the market higher, but this is much different leadership than what elevated the market in 2024. 
Via Talk Markets
Topics ETFs Stocks / Equities
Moderna’s Q4 Losses Worse Than Feared, But Revenue Beat And Cost Cuts Boost Stock — Retail Sentiment Follows
CEO Stéphane Bancel said the company remains focused on driving sales and achieving up to 10 product approvals by 2027, as well as removing nearly $1 billion in costs by the end of this year. 
Via Stocktwits
Communications Have More To Say
Last week was certainly memorable, and it looks like this week is off to a similar start. 
Via Talk Markets
Topics Stocks / Equities
CVS Showered With Upgrades, PT Hikes After Q4 Beat Powers Stock To Best Day In Over 25 Years: Retail Cheer Grows
Analysts largely believe that the company’s Aetna insurance business is set to rebound and its margins will recover soon. 
Via Stocktwits
Biogen Stock Slides To Fresh 12-Year Lows As Profit Outlook Misses, But Retail Snaps Up The Dip
The company's breakthrough Alzheimer's drug, Leqembi, generated $87 million in Q4 sales, well ahead of the $67 million analysts expected. 
Via Stocktwits
Gilead Wins Price-Target Boosts After Solid Q4, Retail Brushes Off Medicare Reform Hit To HIV Drugs
Investors seem encouraged by the company's strong performance in its core business areas and the promise of further growth driven by its expanding pipeline. 
Via Stocktwits
Leading And Lagging Sectors For February 12, 2025
Via Benzinga
Beginnings And Blends: S&P 500 Sector Performance In The New Year
No matter how vast the index landscape becomes, sectors remain central to the conversation. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Vertex Pharma Stock Flooded With Price-Target Hikes After Upbeat Q4 Revenue, 2025 Outlook: Retail Stays Bullish
The company is betting on strong sales of its cystic fibrosis drugs and early traction from its newly approved non-opioid painkiller. 
Via Stocktwits
Merck Stock Heads For 5th Day Of Losses As TD Cowen Downgrades On Gardasil Woes, But Retail Holds Strong
The HPV vaccine had been a key growth driver in China until last year when economic headwinds disrupted demand. 
Via Stocktwits
Leading And Lagging Sectors For February 10, 2025
Via Benzinga
Consumers Are Driving Investors Crazy
2025 is going to drive a lot of investors crazy due to frustrating market behavior and fear. The fear will be real because the source of frustration will be grounded in you, the consumer. It’s already... 
Via Talk Markets
Topics ETFs
Five ETFs to invest in to hedge against policy uncertainty in 2025
With significant policy shifts expected in Washington and ongoing global economic concerns, exchange-traded funds (ETFs) focused on defensive sectors, stable dividends, and geopolitical advantages are... 
Via Talk Markets
Topics ETFs
Leading And Lagging Sectors For February 7, 2025
Via Benzinga
Financials, Health Care Sectors Leading US Stocks Higher In 2025
Genius remains a bull market so far in 2025. All the main sectors in the US equities market are posting year-to-date gains, led by financials and health care, based on a set of ETFs. 
Via Talk Markets
Topics ETFs
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same Page
The analyst sees 2025 as a challenging year due to Eylea headwinds but expects growth to accelerate in 2026, driven by strong eczema treatment sales from the company’s Dupixent drug. 
Via Stocktwits
Bristol-Myers Squibb Stock Slides On Weak 2025 Outlook, Retail Steps In To Buy The Dip
The company announced plans to generate $2 billion in annual cost savings by the end of 2027. 
Via Stocktwits
Leading And Lagging Sectors For February 6, 2025
Via Benzinga
Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat
Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments. 
Via Stocktwits
Leading And Lagging Sectors For February 5, 2025
Via Benzinga
Merck Retail Traders See Buying Opportunity As Stock Dives Toward Worst Day in 17 Years On Weak Guidance
Gardasil, its HPV vaccine, posted a 17% decline in sales to $1.55 billion, primarily due to lower demand in China. 
Via Stocktwits
Pfizer's Retail Traders Cheer Better-Than-Expected Q4 Even As Stock Dips: ‘Another Beat And Still Crazy Cheap'
Under its restructuring program, Pfizer said it remains on track to deliver $4.5 billion in cost savings by the end of 2025. 
Via Stocktwits
Leading And Lagging Sectors For February 4, 2025
Via Benzinga
Can Biotech Stocks Survive The Precarious Macro?
We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows. 
Via Talk Markets
Topics Stocks / Equities World Trade
Exposures Tariff
Leading And Lagging Sectors For February 3, 2025
Via Benzinga
Trump's 25% Tariffs Could Slaughter Canada, Mexico Economies, Hit US Auto Industry, Analysts Warn
Trade war between US, Canada, and Mexico could cause severe economic damage, raise prices, and disrupt supply chains in key industries. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
AbbVie Stock Nears 3-Month High on Q4 Beat As Immunology Growth Eases Humira Slump: Retail Mood Brightens
The company raised its long-term sales outlook for Skyrizi and Rinvoq, now expecting combined revenue of about $24 billion in 2025. 
Via Stocktwits
Leading And Lagging Sectors For January 31, 2025
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback